Advertisements

Buy Cipla, target Rs 650: S Ranganathan

Buy Cipla, target Rs 650: S Ranganathan.....»»

Category: topSource: moneycontrolApr 17th, 2018

Cipla shares gain 7% after company turns profitable in Q4; analysts cut EPS estimates

Cipla shares gain 7% after company turns profitable in Q4; analysts cut EPS estimates.....»»

Category: topSource: moneycontrolMay 23rd, 2018

Buy Muthoot Finance, target Rs 500: S Ranganathan

Buy Muthoot Finance, target Rs 500: S Ranganathan.....»»

Category: topSource: moneycontrolApr 17th, 2018

Top buy sell ideas by Ashwani Gujral, Mitessh Thakkar Prakash Gaba for March 5

Top buy sell ideas by Ashwani Gujral, Mitessh Thakkar Prakash Gaba for March 5.....»»

Category: topSource: moneycontrolMar 4th, 2018

Cipla rallies 7% as global analysts remain positive post Q3 earnings, management commentary

Cipla rallies 7% as global analysts remain positive post Q3 earnings, management commentary.....»»

Category: topSource: moneycontrolFeb 8th, 2018

Top buy sell ideas by Ashwani Gujral, Mitessh Thakkar Prakash Gaba for December 14

Top buy sell ideas by Ashwani Gujral, Mitessh Thakkar Prakash Gaba for December 14.....»»

Category: topSource: moneycontrolDec 13th, 2017

Bull#39;s Eye: Buy IOC, Cipla, SAIL, Godrej Consumer; sell Jubilant Food

Bull#39;s Eye: Buy IOC, Cipla, SAIL, Godrej Consumer; sell Jubilant Food.....»»

Category: topSource: moneycontrolDec 10th, 2017

Buy Cipla; target of Rs 700: Centrum

Buy Cipla; target of Rs 700: Centrum.....»»

Category: topSource: moneycontrolNov 16th, 2017

Buy Cipla Limited; target of Rs 653: Khambatta Securities

Buy Cipla Limited; target of Rs 653: Khambatta Securities.....»»

Category: topSource: moneycontrolAug 23rd, 2017

Cipla jumps 6% after management#39;s FY18 outlook; analysts retain hold rating

Cipla jumps 6% after management#39;s FY18 outlook; analysts retain hold rating.....»»

Category: topSource: moneycontrolAug 14th, 2017

Hold Cipla target Rs 505: Edelweiss Financial Services

Hold Cipla target Rs 505: Edelweiss Financial Services.....»»

Category: marketsSource: economictimesAug 14th, 2017

CLSA upgrades Cipla to "Buy" from "Outperform"; raises target price

CLSA upgrades Cipla to "Buy" from "Outperform"; raises target price.....»»

Category: marketsSource: economictimesAug 14th, 2017

Buy Cipla target Rs 625: Sagar Doshi

Buy Cipla target Rs 625: Sagar Doshi.....»»

Category: marketsSource: economictimesAug 9th, 2017

Top intraday trading ideas for afternoon trade for Wednesday, 9 August 2017

Top intraday trading ideas for afternoon trade for Wednesday, 9 August 2017.....»»

Category: marketsSource: economictimesAug 9th, 2017

Buy Cipla, target Rs 590: Dr CK Narayan

Buy Cipla, target Rs 590: Dr CK Narayan.....»»

Category: marketsSource: economictimesAug 9th, 2017

Amway in Association With Kony Hosted First-ever Hackathon to Advance Digital Transformation in the Industry

Amway in Association With Kony Hosted First-ever Hackathon to Advance Digital Transformation in the Industry.....»»

Category: press-releasesSource: businesswireindiaJul 20th, 2018

GE beats on EPS but trims cash flow target; shares fall

GE beats on EPS but trims cash flow target; shares fall.....»»

Category: global-financeSource: reutersJul 20th, 2018

GE beats diminished profit expectations, trims cash flow target

GE beats diminished profit expectations, trims cash flow target.....»»

Category: global-financeSource: reutersJul 20th, 2018

UiPath Brings Fourth Edition of #UiPathTogether Event in Mumbai

UiPath Brings Fourth Edition of #UiPathTogether Event in Mumbai.....»»

Category: press-releasesSource: businesswireindiaJul 20th, 2018

Bank of Japan"s inflation target dims as prices barely budge

Bank of Japan"s inflation target dims as prices barely budge.....»»

Category: global-financeSource: reutersJul 19th, 2018

New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis

New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis.....»»

Category: press-releasesSource: businesswireindiaJul 19th, 2018